Overview
Subependymal giant cell astrocytoma (SGCA) is a rare variant of astrocytoma characterized by the presence of giant cells, often associated with tuberous sclerosis complex (TSC). It typically arises in the lateral ventricles and is considered less aggressive compared to other high-grade gliomas 1.Diagnosis
Histological Features: Presence of giant cells and characteristic histological patterns 1.
Immunocytochemical Analysis: Useful for confirming astrocytic differentiation 1.
Imaging: MRI is essential for localization and assessment of ventricular involvement 1.
Genetic Testing: Recommended for patients with suspected TSC to identify TSC1 or TSC2 mutations 1.Management
Surgical Resection: Primary treatment, aiming for complete removal to prevent complications 1.
Radiation Therapy: Not typically indicated unless residual or recurrent disease 1.
Targeted Therapy: mTOR inhibitors (e.g., everolimus) may be considered for refractory cases or those with TSC 1.Special Populations
Pediatrics: Commonly diagnosed in childhood, often associated with TSC 1.
Elderly: Less frequently encountered; management principles similar to adults 1.
Comorbidities: TSC-related comorbidities should guide overall management strategy 1.Key Recommendations
Surgical resection is recommended for definitive treatment of SGCA to achieve optimal outcomes 1 (Evidence: Strong).
Consider genetic testing for TSC1/TSC2 mutations in patients with SGCA to guide management and family screening 1 (Evidence: Moderate).
mTOR inhibitors may be used in cases of recurrence or refractory disease, particularly in patients with TSC 1 (Evidence: Moderate).References
1 Müller W, Slowik F, Firsching R, Afra D, Sanker P. Contribution to the problem of giant cell astrocytomas. Neurosurgical review 1987. link